Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 363-369

  De Jong, Wouter K ^a   Verpooten, Gonda F ^b   Kramer, Henk ^a   Louwagie, Joost ^b   Groen, Harry J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b OncoMethylome Sciences SA   (Belgium)

Author keywords

Bronchial epithelial cells; Clonal field expansion; Endobronchial brush; Methylation specific pcr; Non small cell lung cancer; Promoter methylation

Indexed keywords

APC 2 PROTEIN; APC PROTEIN; CELL PROTEIN; CHECKPOINT WITH FORKHEAD AND RING FINGER DOMAIN; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE 2A INHIBITOR; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA 2; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 5; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRONCHUS MUCOSA; BRUSH BORDER; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ISOLATION; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; GENE FREQUENCY; GENE LOCATION; HUMAN; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; TISSUE DISTRIBUTION; TUMOR CELL;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 61449209083     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
2. Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 707-717, 2004.
3. Tsou JA, Hagen JA, Carpenter CL et al: DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21: 5450-5461, 2002.
4. Shames DS, Girard L, Gao B et al: A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e486, 2006.
5. Guo M, House MG, Hooker C et al: Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res 10: 5131-5136, 2004.
6. Zochbauer-Muller S, Fong KM, Virmani AK et al: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255, 2001.
7. Pellise M, Castells A, Gines A et al: Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonography-guided fine-needle aspiration biopsy. Clin Cancer Res 10: 4444-4449, 2004.
8. Harden SV, Tokumaru Y, Westra WH et al: Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 9: 1370-1375, 2003.
9. Kersting M, Friedl C, Kraus A et al: Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 18: 3221-3229, 2000.
10. Esteller M, Sanchez-Cespedes M, Rosell R et al: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59: 67-70, 1999.
11. Topaloglu O, Hoque MO, Tokumaru Y et al: Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 10: 2284-2288, 2004.
12. Kim H, Kwon YM, Kim JS et al: Tumor-specific methylation in bronchial lavage for the early detection of non-small cell lung cancer. J Clin Oncol 22: 2363-2370, 2004.
13. Grote HJ, Schmiemann V, Geddert H et al: Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer. Int J Cancer 116: 720-725, 2005.
14. Schmiemann V, Booking A, Kazimirek M et al: Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clin Cancer Res 11: 7728-7734, 2005.
15. Palmisano WA, Divine KK, Saccomanno G et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958, 2000.
16. Olaussen KA, Soria JC, Park YW et al: Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC. Eur J Cancer 41: 2112-2119, 2005.
17. Zochbauer-Muller S, Lam S, Toyooka S et al: Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 107: 612-616, 2003.
18. Soria JC, Rodriguez M, Liu DD et al: Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 62: 351-355, 2002.
19. Belinsky SA, Liechty KC, Gentry FD et al: Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66: 3338-3344, 2006.
20. Belinsky SA, Palmisano WA, Gilliland FD et al: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370-2377, 2002.
21. Kim DH, Nelson HH, Wiencke JK et al: p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61: 3419-3424, 2001.
22. Yanagawa N, Tamura G, Oizumi H et al: Promoter hyper-methylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 58: 131-138, 2007.
23. Liu Y, Gao W, Siegfried JM et al: Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. BMC Cancer 7: 74, 2007.
24. Braakhuis BJ, Tabor MP, Kummer JA et al: A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63: 1727-1730, 2003.
25. Slaughter DP, Southwick HW and Smejkal W: Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6: 963-968, 1953.
26. Elssner A, Jaumann F, Wolf WP et al: Bronchial epithelial cell B7-1 and B7-2 mRNA expression after lung transplantation: a role in allograft rejection? Eur Respir J 20: 165-169, 2002.
27. Spira A, Beane J, Shah V et al: Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci USA 101: 10143-10148, 2004.
28. Herman JG, Graff JR, Myohanen S et al: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
29. Toyooka S, Maruyama R, Toyooka KO et al: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103: 153-160, 2003.
30. Spira A, Beane JE, Shah V et al: Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 13: 361-366, 2007.
31. Belinsky SA, Nikula KJ, Palmisano WA et al: Aberrant methylation p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896, 1998.
32. Belinsky SA, Klinge DM, Dekker JD et al: Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11: 6505-6511, 2005.
33. Cirincione R, Lintas C, Conte D et al: Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: A nested case-control study. Int J Cancer 118: 1248-1253, 2006.
34. Destro A, Bianchi P, Alloisio M et al: K-ras and p16(INK4A) alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 44: 23-32, 2004.
35. Grote HJ, Schmiemann V, Kiel S et al: Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer. Int J Cancer 110: 751-755, 2004.
36. Russo AL, Thiagalingam A, Pan H et al: Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res 11: 2466-2470, 2005.
37. Shivapurkar N, Stastny V, Suzuki M et al: Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 247: 56-71, 2007.
38. Gu J, Berman D, Lu C et al: Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12: 7329-7338, 2006.
39. Hoque MO, Topaloglu O, Begum S et al: Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23: 6569-6575, 2005.
40. Divine KK, Pulling LC, Marron-Terada PG et al: Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer 114: 400-405, 2005.
41. Kim JS, Kim H, Shim YM et al: Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis, 2004.
42. Tomizawa Y, lijima H, Nomoto T et al: Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer 46: 305-312, 2004.